Blog

SINGAPORE, APRIL 21 Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI). Moleac is dedicated in...

In November 2020, ESO-WSO provided scientific updates to Health Care Practitioners. During this conference, 4 abstracts on NeuroAiD’s safety and efficacy in post-stroke recovery are presented by international speakers.  

World Stroke Day 2020 Stroke remains one of the main cause for disability worldwide. Moleac remains committed to helping patients Reconnect with their loved ones. We always place patients at the center of everything we do, and their journey towards full recovery is...